Navigation Links
Amarillo Biosciences Announces Plan to Open Asia Operations Center in Taipei, Taiwan
Date:6/26/2012

AMARILLO, Texas, June 26, 2012 /PRNewswire/ -- Amarillo Biosciences, Inc. (ABI) (OTCBB: AMAR) today announced a plan to open its Asia Operations Center in Taipei, Taiwan. This new center will enable ABI to increase its presence in Taiwan in order to access growing markets in mainland China and in other Asian countries.

Dr. Stephen Chen, ABI's Chairman & CEO, said, "This new Asia Operations Center will explore new business opportunities in Asia, seek licensing opportunities, and evaluate investment proposals. Interviews for its new staff will begin immediately in an effort to have the center fully operational in the third quarter of this year." 

"The new staff will include a general manager, scientific and business administrators, and numerous project managers," Dr. Chen added.

The mission of the Asia Operations Center is fourfold.  First, the Asia Center will introduce novel healthcare products and technologies from the U.S. into the Asian markets. Second, the Asia Center will be responsible for identifying and developing new strategic partners in the region.  Third, the Center will be poised to seek out new sources of financing when the need arises.  Fourth, the Asia Center will identify new healthcare products and technologies that can be brought into the U.S. from the Asian regions to be distributed by ABI.About Amarillo Biosciences
Amarillo Biosciences, Inc. is a U.S. biotechnology firm operating in global partnership with Hayashibara Company, Ltd., a wholly-owned subsidiary of the Nagase Group, which also holds 4% of Amarillo Biosciences shares and has provided over $18 million in loans, grants and equity investments. The Company's primary focus is ongoing R&D into the use of low-dose, orally administered interferon as a treatment for a variety of conditions, including influenza, hepatitis C, chronic cough, and opportunistic infections in patients who are HIV positive. The Company has invested nearly $40 million to establish oral interferon as a therapeutic agent. The majority of those funds were invested in clinical trials in an effort to achieve FDA approval for interferon. Additional information is available on the web at http://www.amarbio.com/.

Except for the historical information contained herein, the matters discussed in this news release are forward-looking statements that involve risks and uncertainties, including uncertainties related to product development, uncertainties related to the need for regulatory and other government approvals, dependence on proprietary technology, uncertainty of market acceptance of oral interferon or the Company's other product candidates and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission. In particular, see "Item 1. Description of Business" and "Item 7A. Qualitative and Quantitative Disclosures about Market Risk" of the Company's Form 10-K for the fiscal year ended December 31, 2011.  Investor Relations: Philippe Niemetz

Stephen T. Chen, Ph.D.PAN Consultants, Ltd.

Chairman and CEOemail: p.niemetz@panconsultants.com

e-mail: STCACTS@yahoo.com Tel: 212-344-6464

Tel: 626-407-2570Fax: 212-618-1276 Bernard Cohen Vice President & CFO email: bcohen@amarbio.com Tel: 806-376-1741 ext. 16 Fax: 806-376-9301


'/>"/>
SOURCE Amarillo Biosciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Amarillo Biosciences Appoints Dr. Stephen Chen as Chairman and CEO
2. Ambit Biosciences Names Michael A. Martino President and Chief Executive Officer
3. The Law Firm of Levi & Korsinsky, LLP Launches an Investigation Into Possible Securities Laws Violations by Pacific Biosciences of California, Inc.
4. Coronado Biosciences to Present at the Oppenheimer 22nd Annual Healthcare Conference
5. Coronado Biosciences Announces Phase 1 Results of CNDO-109 in AML to be Presented at the American Society of Hematology
6. Sangamo BioSciences Announces Presentation of New Data from ZFP Therapeutic® Program in Hemophilia B at American Society for Hematology Meeting
7. Sangamo BioSciences Announces Presentation at J.P. Morgan Healthcare Conference
8. Sofie Biosciences Is Awarded a US Patent on a Family of Novel PET Probes for Use in Oncology and Immunology
9. Sangamo BioSciences Announces Fourth Quarter and Full Year 2011 Conference Call and Webcast
10. Neurocrine Biosciences to Present at the 14th Annual BIO CEO & Investor Conference
11. Ambit Biosciences to Present at Two Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... Dec. 2, 2016 More than $4.3 million was ... Medals dinner ( DHMD ). The gala was held at the ... York City and honored Alan Alda ... to health and medicine and the public understanding of science. ... 2006, the event has raised $40 million for the Laboratory,s ...
(Date:12/2/2016)... ... 2016 , ... ACEA Biosciences, Inc. announced today that it will be presenting ... the World Conference on Lung Cancer 2016, taking place in Vienna, Austria December 3rd-8th. ... trials for AC0010 in patients with advanced non-small cell lung cancer harboring the EGFR ...
(Date:12/2/2016)... ... December 01, 2016 , ... DrugDev believes the ... and a beautiful technology experience. All three tenets were on display at the 2nd ... leaders from over 40 sponsor, CRO and site organizations to discuss innovation and the ...
(Date:12/2/2016)... December 2, 2016 The immunohistochemistry (IHC) ... at a CAGR of 7.3% during the forecast period of 2016 ... diagnostic laboratories segment accounted for the largest share of immunohistochemistry (IHC) ... , ... global immunohistochemistry (IHC) market spread across 225 pages, profiling 10 companies ...
Breaking Biology Technology:
(Date:6/21/2016)... Columbia , June 21, 2016 ... to the new role of principal product architect ... named the director of customer development. Both will ... chief technical officer. The moves reflect NuData,s strategic ... in response to high customer demand and customer ...
(Date:6/15/2016)... June 15, 2016 Transparency ... titled "Gesture Recognition Market by Application Market - Global Industry Analysis ... 2024". According to the report, the  global gesture recognition ... 2015 and is estimated to grow at a ... by 2024.  Increasing application of gesture ...
(Date:6/7/2016)... -- Syngrafii Inc. and San Antonio Credit Union (SACU) ... Syngrafii,s patented LongPen™ eSignature "Wet" solution into SACU,s ... in greater convenience for SACU members and operational ... document workflow and compliance requirements. Logo ... Highlights: ...
Breaking Biology News(10 mins):